Literature DB >> 32950203

Utility of Cardiac Magnetic Resonance Imaging Versus Cardiac Positron Emission Tomography for Risk Stratification for Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis.

Zain Gowani1, Mohammadali Habibi1, David R Okada1, John Smith1, Arsalan Derakhshan1, Stefan L Zimmerman2, Satish Misra1, Nisha A Gilotra1, Ronald D Berger1, Hugh Calkins1, Harikrishna Tandri1, Jonathan Chrispin3.   

Abstract

Abnormalities on cardiac magnetic resonance imaging (CMR) and positron emission tomography (PET) predict ventricular arrhythmias (VA) in patients with cardiac sarcoidosis (CS). Little is known whether concurrent abnormalities on CMR and PET increases the risk of developing VA. Our aim was to compare the additive utility of CMR and PET in predicting VA in patients with CS. We included all patients treated at our institution from 2000 to 2018 who (1) had probable or definite CS and (2) had undergone both CMR and PET. The primary endpoint was VA at follow up, which was defined as sustained ventricular tachycardia, sudden cardiac death, or any appropriate device tachytherapy. Fifty patients were included, 88% of whom had a left ventricular ejection fraction >35%. During a mean follow-up 4.1 years, 7/50 (14%) patients had VA. The negative predictive value of LGE for VA was 100% and the negative predictive value of FDG for VA was 79%. Among groups, VA occurred in 4/21 (19%) subjects in the LGE+/FDG+ group, 3/14 (21%) in the LGE+/FDG- group, and 0/15 (0%) in the FDG+/LGE- group. There were no LGE-/FDG- patients. In conclusion, CMR may be the preferred initial clinical risk stratification tool in patients with CS. FDG uptake without LGE on initial imaging may not add additional prognostic information regarding VA risk.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32950203     DOI: 10.1016/j.amjcard.2020.08.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis.

Authors:  Yuta Kobayashi; Takuma Sato; Toshiyuki Nagai; Kenji Hirata; Satonori Tsuneta; Yoshiya Kato; Hirokazu Komoriyama; Kiwamu Kamiya; Takao Konishi; Kazunori Omote; Hiroshi Ohira; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2021-09-12

2.  Is positron emission tomography enough to rule out cardiac sarcoidosis? A case report.

Authors:  Siyi Huang; Siri Kunchakarra; Ankit Rathod
Journal:  Eur Heart J Case Rep       Date:  2021-09-13

Review 3.  Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis.

Authors:  Alison L Wand; Jonathan Chrispin; Elie Saad; Monica Mukherjee; Allison G Hays; Nisha A Gilotra
Journal:  Front Cardiovasc Med       Date:  2022-01-27

Review 4.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

Review 5.  Extrapulmonary sarcoidosis with a focus on cardiac, nervous system, and ocular involvement.

Authors:  John A Belperio; Faisal Shaikh; Fereidoun Abtin; Michael C Fishbein; Rajan Saggar; Edmund Tsui; Joseph P Lynch
Journal:  EClinicalMedicine       Date:  2021-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.